Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. PIM1/HDAC6 compound 22
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. PIM1/HDAC6 compound 22: sourced facts only. name: "Among them, compound 22 exhibited potent antiproliferative activity in MV4-11 cells, along with robust inhibitory effects against both PIM1 and HDAC6."; target: "Among them, compound 22 exhibited potent antiproliferative activity in MV4-11 cells, along with robust inhibitory effects against both PIM1 and HDAC6."; target: "Among them, compound 22 exhibited potent antiproliferative activity in MV4-11 cells, along with robust inhibitory effects against both PIM1 and HDAC6."; developer: "Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China."; stage: "Furthermore, 22 demonstrated significant anticancer efficacy (TGI = 81.3%; 50 mg/kg, QD) in the MV4-11 xenograft model without notable toxicity."
02
Targets
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Go deeper on China Pharma Univ. PIM1/HDAC6 compound 22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. PIM1/HDAC6 compound 22.
Work on China Pharma Univ. PIM1/HDAC6 compound 22? Claim this page to correct or add information. Claim this page